Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study

Abstract P5-10-06: Risk of recurrence estimates with IHC4 are tolerant of variations in staining and scoring

(2015) Andrew Dodson et al.   CANCER RESEARCH

Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer

(2014) J Stephen et al.   BRITISH JOURNAL OF CANCER

An International Ki67 Reproducibility Study

(2013) Mei-Yin C. Polley et al.   JNCI-Journal of the National Cancer Institute

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

(2012) S Barton et al.   BRITISH JOURNAL OF CANCER

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

(2011) K. S. Saini et al.   ANNALS OF ONCOLOGY

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses

(2011) H.E. Campbell et al.   EUROPEAN JOURNAL OF CANCER

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative validation of the SP6 antibody to Ki67 in breast cancer

(2010) L. Zabaglo et al.   JOURNAL OF CLINICAL PATHOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY